Objective. To provide a comprehensive review of the clinical use of the recombinant biological agent, palifermin, with particular reference to its use in its approved indication, oral mucositis resulting from high dose chemotherapy and radiation in patients with hematologic malignancies requiring hematopoietic stem cell support.
Data Sources. A MEDLINE search was conducted using the terms ‘palifermin’ and ‘Kepivance.’ All data available from MEDLINE were reviewed. The reference lists from retrieved articles were reviewed and other relevant papers were identified.
Data Summary. Keratinocyte growth factor (KGF) is a growth factor that acts specifically on epithelial cells playing a role in proliferation, migration, and morphogenesis. Palifermin is a recombinant human form of KGF. Because of its ability to cause proliferation of the oral mucosa and to protect against mucosal injury, palifermin is a treatment option for patients who are at high risk for oral mucositis, specifically patients with hematological malignancies receiving stem cell transplantation (SCT). In a phase III study of these patients, the overall incidence of World Health Organization (WHO) grade 3 or 4 oral mucositis was significantly reduced in the palifermin group (palifermin=63% versus placebo=98%, P B0.001). Among the patients who experienced WHO grade 3 or 4 oral mucositis the average duration of this grade of mucositis in the palifermin group was six days compared with nine days in the placebo group (P B0.001). Common adverse effects of palifermin include pruritis, erythema, mouth and tongue disorders, and taste alterations.
Dodd MJ.The pathogenesis and characterization of oral mucositis associated with cancer therapy. Oncol Nurs Forum2004; 31 (suppl 4): 5-11.
2.
Salvador PT.Factors influencing the incidence and severity of oral mucositis in patients undergoing auto-logous stem cell transplantation. Can Oncol Nurs J2005; 15: 29-34.
3.
Bolwell BJ, Kalaycio M, Sobecks R, et al.A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant2002; 30: 587-591.
4.
Gabriel DA, Shea T, Olajida O, Serody JS, Comeau T.The effect of oral mucositis on morbidity and mortality in bone marrow transplant. Semin Oncol2003; 30 (suppl 18): 76-83.
5.
Woo SB, Sonis ST, Monopoli MM, Sonis AL.A longitudinal study of oral ulcerative mucositis in bone marrow transplant recipients. Cancer1993; 72: 1612-1617.
6.
Sonis ST, Oster G, Fuchs H, et al.Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Onc2001; 19: 2201-2205.
7.
Rapoport AP, Watelet LF, Linder T, et al.Analysis of factors that correlate with mucositis in recipients of autologous and allogeneic stem-cell transplants. J Clin Onc1999; 17: 2446-2453.
8.
Rubenstein EB, Peterson DE, Schubert M, et al.Clinical practice guidelines for the prevention and treatment of cancer therapy-induced oral and gastrointestinal mucositis. Cancer2004; 100: 2026-2046.
9.
Peterson DE, Cariello A.Mucosal damage: a major risk factor for severe complications after cytotoxic therapy. Semin Oncol2004; 31: 35-44.
10.
Rubin JS, Osada H, Finch PW, et al.Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci1989; 86: 802-806.
11.
Finch PW, Rubin JS, Miki T, Ron D, Aaronson SA.Human KGF is FGF-related with properties of a paracrine effector of epithelial cell growth. Science1989; 245: 752-755.
12.
Playford RJ, Marchbank T, Mandir N, et al.Effects of keratinocyte growth factor (KGF) on gut growth and repair. J Pathol1998; 184: 316-322.
13.
Danilenko DM.Preclinical and early clinical development of keratinocyte growth factor, an epithelial-specific tissue growth factor. Toxicol Pathol1999; 27: 64-71.
14.
Farrell CL, Bready JV, Rex KL, et al.Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res1998; 58: 933-939.
15.
Kepivance Package Insert, Amgen 2004.
16.
Miki T, Bottaro DP, Fleming TP.Determination of ligand-binding specificity by alternative splicing: two distinct growth factor receptors encoded by a single gene. Proc Natl Acad Sci1992; 89: 246-250.
17.
Hille A, Rave-Frank M, Pradier O, et al.Effect of keratinocyte growth factor on the proliferation, clonogenic capacity and colony size of human epithelial tumour cells in vitro. Int J Radiat Biol2003; 79: 119-128.
18.
Serdar CM, Heard R, Prathikanti D, et al.Safety, pharmacokinetics and biological activity of rHuKGF in normal volunteers: Results of a placebo-controlled randomized double-blind phase 1 study. Blood1997; 90, 172a-172a (abstr).
19.
Spielberger RT, Stiff P, Bensinger W, et al.Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med2004; 351: 2590-2598.
20.
Meropol NJ, Somer RA, Gutheil J, et al.Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: potential role as mucosal protectant. J Clin Onc2003; 21: 1452-1458.
21.
Clarke SJ, Abdi E, Davis ID, et al.Recombinant human keratinocyte growth factor (rHuKGF) prevents chemotherapy-induced mucositis in patients with advanced colorectal cancer: a randomized phase II trial. Proc Am Clin Oncol2001; 20: 383a-383a (abstr).
22.
Brizel DM, Herman T, Goffinet D, et al.A phase I/II trial of escalating doses of recombinant human keratinocyte growth factor (rHuKGF) in head and neck (HNC) patients receiving radiotherapy (RT) with concurrent chemotherapy (CT). Int J Radiat Oncol Biol Phys2001; 51 (suppl 1): abstr 40.
23.
Brizel DM, Le QT, Rosenthal D, et al.Phase II study of recombinant human keratinocyte growth factor (rHuKGF) in head and neck cancer treated with standard (SRT) or hyperfactionated irradiation (HRT) and concurrent chemotherapy (CT). Int J Radiat Oncol Biol Phys2002; 54 (suppl 1): 285-286.
24.
Hohlfeld JM, Hoymann HG, Tschernig T, et al.Keratinocyte growth factor transiently alters pulmonary function in rats. J Appl Physiol2004; 96: 704-710.
